Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure

Motoaki Sano, Sam C. Wang, Manabu Shirai, Fernando Scaglia, Min Xie, Satoshi Sakai, Toru Tanaka, Prathit A. Kulkarni, Philip M. Barger, Keith A. Youker, George E. Taffet, Yasuo Hamamori, Lloyd H. Michael, William J. Craigen, Michael D. Schneider

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Hypertrophy allows the heart to adapt to workload but culminates in later pump failure; how it is achieved remains uncertain. Previously, we showed that hypertrophy is accompanied by activation of cyclin T/Cdk9, which phosphorylates the C-terminal domain of the large subunit of RNA polymerase II, stimulating transcription elongation and pre-mRNA processing; Cdk9 activity was required for hypertrophy in culture, whereas heart-specific activation of Cdk9 by cyclin T1 provoked hypertrophy in mice. Here, we report that αMHC-cyclin T1 mice appear normal at baseline yet suffer fulminant apoptotic cardiomyopathy when challenged by mechanical stress or signaling by the G-protein Gq. At pathophysiological levels, Cdk9 activity suppresses many genes for mitochondrial proteins including master regulators of mitochondrial function (peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1), nuclear respiratory factor-1). In culture, cyclin T1/Cdk9 suppresses PGC-1, decreases mitochondrial membrane potential, and sensitizes cardiomyocytes to apoptosis, effects rescued by exogenous PGC-1. Cyclin T1/Cdk9 inhibits PGC-1 promoter activity and preinitiation complex assembly. Thus, chronic activation of Cdk9 causes not only cardiomyocyte enlargement but also defective mitochondrial function, via diminished PGC-1 transcription, and a resulting susceptibility to apoptotic cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)3559-3569
Number of pages11
JournalEMBO Journal
Volume23
Issue number17
DOIs
StatePublished - Sep 1 2004

Fingerprint

Cyclin T
Heart Failure
Chemical activation
Hypertrophy
Transcription
Cardiomyopathies
Cardiac Myocytes
Nuclear Respiratory Factor 1
Mechanical Stress
Mitochondrial Membrane Potential
Mitochondrial Proteins
RNA Precursors
Cardiomegaly
Workload
GTP-Binding Proteins
Elongation
Genes
Pumps
Apoptosis
Membranes

Keywords

  • Cardiac
  • Cyclin T
  • Cyclin-dependent kinase-9
  • Heart failure
  • Mitochondria

ASJC Scopus subject areas

  • Neuroscience(all)
  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Sano, M., Wang, S. C., Shirai, M., Scaglia, F., Xie, M., Sakai, S., ... Schneider, M. D. (2004). Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO Journal, 23(17), 3559-3569. https://doi.org/10.1038/sj.emboj.7600351

Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. / Sano, Motoaki; Wang, Sam C.; Shirai, Manabu; Scaglia, Fernando; Xie, Min; Sakai, Satoshi; Tanaka, Toru; Kulkarni, Prathit A.; Barger, Philip M.; Youker, Keith A.; Taffet, George E.; Hamamori, Yasuo; Michael, Lloyd H.; Craigen, William J.; Schneider, Michael D.

In: EMBO Journal, Vol. 23, No. 17, 01.09.2004, p. 3559-3569.

Research output: Contribution to journalArticle

Sano, M, Wang, SC, Shirai, M, Scaglia, F, Xie, M, Sakai, S, Tanaka, T, Kulkarni, PA, Barger, PM, Youker, KA, Taffet, GE, Hamamori, Y, Michael, LH, Craigen, WJ & Schneider, MD 2004, 'Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure', EMBO Journal, vol. 23, no. 17, pp. 3559-3569. https://doi.org/10.1038/sj.emboj.7600351
Sano, Motoaki ; Wang, Sam C. ; Shirai, Manabu ; Scaglia, Fernando ; Xie, Min ; Sakai, Satoshi ; Tanaka, Toru ; Kulkarni, Prathit A. ; Barger, Philip M. ; Youker, Keith A. ; Taffet, George E. ; Hamamori, Yasuo ; Michael, Lloyd H. ; Craigen, William J. ; Schneider, Michael D. / Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. In: EMBO Journal. 2004 ; Vol. 23, No. 17. pp. 3559-3569.
@article{a9332dd3fb72464d82a3ac8ef670912a,
title = "Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure",
abstract = "Hypertrophy allows the heart to adapt to workload but culminates in later pump failure; how it is achieved remains uncertain. Previously, we showed that hypertrophy is accompanied by activation of cyclin T/Cdk9, which phosphorylates the C-terminal domain of the large subunit of RNA polymerase II, stimulating transcription elongation and pre-mRNA processing; Cdk9 activity was required for hypertrophy in culture, whereas heart-specific activation of Cdk9 by cyclin T1 provoked hypertrophy in mice. Here, we report that αMHC-cyclin T1 mice appear normal at baseline yet suffer fulminant apoptotic cardiomyopathy when challenged by mechanical stress or signaling by the G-protein Gq. At pathophysiological levels, Cdk9 activity suppresses many genes for mitochondrial proteins including master regulators of mitochondrial function (peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1), nuclear respiratory factor-1). In culture, cyclin T1/Cdk9 suppresses PGC-1, decreases mitochondrial membrane potential, and sensitizes cardiomyocytes to apoptosis, effects rescued by exogenous PGC-1. Cyclin T1/Cdk9 inhibits PGC-1 promoter activity and preinitiation complex assembly. Thus, chronic activation of Cdk9 causes not only cardiomyocyte enlargement but also defective mitochondrial function, via diminished PGC-1 transcription, and a resulting susceptibility to apoptotic cardiomyopathy.",
keywords = "Cardiac, Cyclin T, Cyclin-dependent kinase-9, Heart failure, Mitochondria",
author = "Motoaki Sano and Wang, {Sam C.} and Manabu Shirai and Fernando Scaglia and Min Xie and Satoshi Sakai and Toru Tanaka and Kulkarni, {Prathit A.} and Barger, {Philip M.} and Youker, {Keith A.} and Taffet, {George E.} and Yasuo Hamamori and Michael, {Lloyd H.} and Craigen, {William J.} and Schneider, {Michael D.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1038/sj.emboj.7600351",
language = "English (US)",
volume = "23",
pages = "3559--3569",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "17",

}

TY - JOUR

T1 - Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure

AU - Sano, Motoaki

AU - Wang, Sam C.

AU - Shirai, Manabu

AU - Scaglia, Fernando

AU - Xie, Min

AU - Sakai, Satoshi

AU - Tanaka, Toru

AU - Kulkarni, Prathit A.

AU - Barger, Philip M.

AU - Youker, Keith A.

AU - Taffet, George E.

AU - Hamamori, Yasuo

AU - Michael, Lloyd H.

AU - Craigen, William J.

AU - Schneider, Michael D.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Hypertrophy allows the heart to adapt to workload but culminates in later pump failure; how it is achieved remains uncertain. Previously, we showed that hypertrophy is accompanied by activation of cyclin T/Cdk9, which phosphorylates the C-terminal domain of the large subunit of RNA polymerase II, stimulating transcription elongation and pre-mRNA processing; Cdk9 activity was required for hypertrophy in culture, whereas heart-specific activation of Cdk9 by cyclin T1 provoked hypertrophy in mice. Here, we report that αMHC-cyclin T1 mice appear normal at baseline yet suffer fulminant apoptotic cardiomyopathy when challenged by mechanical stress or signaling by the G-protein Gq. At pathophysiological levels, Cdk9 activity suppresses many genes for mitochondrial proteins including master regulators of mitochondrial function (peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1), nuclear respiratory factor-1). In culture, cyclin T1/Cdk9 suppresses PGC-1, decreases mitochondrial membrane potential, and sensitizes cardiomyocytes to apoptosis, effects rescued by exogenous PGC-1. Cyclin T1/Cdk9 inhibits PGC-1 promoter activity and preinitiation complex assembly. Thus, chronic activation of Cdk9 causes not only cardiomyocyte enlargement but also defective mitochondrial function, via diminished PGC-1 transcription, and a resulting susceptibility to apoptotic cardiomyopathy.

AB - Hypertrophy allows the heart to adapt to workload but culminates in later pump failure; how it is achieved remains uncertain. Previously, we showed that hypertrophy is accompanied by activation of cyclin T/Cdk9, which phosphorylates the C-terminal domain of the large subunit of RNA polymerase II, stimulating transcription elongation and pre-mRNA processing; Cdk9 activity was required for hypertrophy in culture, whereas heart-specific activation of Cdk9 by cyclin T1 provoked hypertrophy in mice. Here, we report that αMHC-cyclin T1 mice appear normal at baseline yet suffer fulminant apoptotic cardiomyopathy when challenged by mechanical stress or signaling by the G-protein Gq. At pathophysiological levels, Cdk9 activity suppresses many genes for mitochondrial proteins including master regulators of mitochondrial function (peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1), nuclear respiratory factor-1). In culture, cyclin T1/Cdk9 suppresses PGC-1, decreases mitochondrial membrane potential, and sensitizes cardiomyocytes to apoptosis, effects rescued by exogenous PGC-1. Cyclin T1/Cdk9 inhibits PGC-1 promoter activity and preinitiation complex assembly. Thus, chronic activation of Cdk9 causes not only cardiomyocyte enlargement but also defective mitochondrial function, via diminished PGC-1 transcription, and a resulting susceptibility to apoptotic cardiomyopathy.

KW - Cardiac

KW - Cyclin T

KW - Cyclin-dependent kinase-9

KW - Heart failure

KW - Mitochondria

UR - http://www.scopus.com/inward/record.url?scp=4644231687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644231687&partnerID=8YFLogxK

U2 - 10.1038/sj.emboj.7600351

DO - 10.1038/sj.emboj.7600351

M3 - Article

C2 - 15297879

AN - SCOPUS:4644231687

VL - 23

SP - 3559

EP - 3569

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 17

ER -